NAV

Butenoic Acid

Identification

Generic Name
Butenoic Acid
DrugBank Accession Number
DB02074
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 86.0892
Monoisotopic: 86.036779436
Chemical Formula
C4H6O2
Synonyms
Not Available
External IDs
  • FEMA NO. 3908
  • NSC-206946
  • NSC-8751

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
PathwayCategory
Fatty Acid BiosynthesisMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as straight chain fatty acids. These are fatty acids with a straight aliphatic chain.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acids and conjugates
Direct Parent
Straight chain fatty acids
Alternative Parents
Unsaturated fatty acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic oxide / Organic oxygen compound / Organooxygen compound / Straight chain fatty acid
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
2-butenoic acid (CHEBI:41131) / Unsaturated fatty acids (LMFA01030195)
Affected organisms
Not Available

Chemical Identifiers

UNII
YW5WZZ4O5Q
CAS number
107-93-7
InChI Key
LDHQCZJRKDOVOX-NSCUHMNNSA-N
InChI
InChI=1S/C4H6O2/c1-2-3-4(5)6/h2-3H,1H3,(H,5,6)/b3-2+
IUPAC Name
(2E)-but-2-enoic acid
SMILES
C\C=C\C(O)=O

References

Synthesis Reference

Wolfgang Krause, Hansgeorg Ernst, Joachim Paust, Udo Rheude, Walter Dobler, "Preparation of alkylesters of 0,0-dialkyl-4-phosphono-2-methyl-2-butenoic acid and alkyl esters of 4-halo-2-methyl-2-butenoic acid containing a high percentage of E isomers." U.S. Patent US5717128, issued November, 1971.

US5717128
General References
Not Available
Human Metabolome Database
HMDB0010720
KEGG Compound
C01771
PubChem Compound
637090
PubChem Substance
46505990
ChemSpider
552744
BindingDB
50427207
ChEBI
41131
ChEMBL
CHEMBL1213528
ZINC
ZINC000000901132
PDBe Ligand
BEO
PDB Entries
1lfo / 6hji

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)72 °CPhysProp
boiling point (°C)184.7 °CPhysProp
water solubility9.4E+004 mg/L (at 25 °C)RIDDICK,JA ET AL. (1986)
pKa4.17 (at 18 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility101.0 mg/mLALOGPS
logP0.94ALOGPS
logP0.92Chemaxon
logS0.07ALOGPS
pKa (Strongest Acidic)4.71Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area37.3 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity22.96 m3·mol-1Chemaxon
Polarizability8.44 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9923
Blood Brain Barrier+0.9624
Caco-2 permeable+0.6066
P-glycoprotein substrateNon-substrate0.8364
P-glycoprotein inhibitor INon-inhibitor0.9822
P-glycoprotein inhibitor IINon-inhibitor0.9849
Renal organic cation transporterNon-inhibitor0.9473
CYP450 2C9 substrateNon-substrate0.7332
CYP450 2D6 substrateNon-substrate0.9515
CYP450 3A4 substrateNon-substrate0.7887
CYP450 1A2 substrateNon-inhibitor0.9227
CYP450 2C9 inhibitorNon-inhibitor0.9526
CYP450 2D6 inhibitorNon-inhibitor0.9707
CYP450 2C19 inhibitorNon-inhibitor0.9816
CYP450 3A4 inhibitorNon-inhibitor0.9748
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9839
Ames testNon AMES toxic0.9133
CarcinogenicityCarcinogens 0.6536
BiodegradationReady biodegradable0.8123
Rat acute toxicity1.9038 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.97
hERG inhibition (predictor II)Non-inhibitor0.9893
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-000l-9000000000-c066ee0b8aa28cc564f5
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-9000000000-139e86f163451c657b84
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-9000000000-b1e1c9a0bcfd328b1cd9
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9000000000-e0d8bcef7823a57ace6b
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-9000000000-f496e2b96544aa9df21d
13C NMR Spectrum1D NMRNot Applicable

Carriers

Details1. Fatty acid-binding protein, liver
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Phospholipid binding
Specific Function
Plays a role in lipoprotein-mediated cholesterol uptake in hepatocytes (PubMed:25732850). Binds cholesterol (PubMed:25732850). Binds free fatty acids and their coenzyme A derivatives, bilirubin, an...
Gene Name
FABP1
Uniprot ID
P07148
Uniprot Name
Fatty acid-binding protein, liver
Molecular Weight
14208.34 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52